Univariate analysis of complete count recovery at 1 month from CAR T-cell infusion
| . | Complete count recovery (n = 20) . | No complete count recovery (n = 63) . | P . |
|---|---|---|---|
| Age, median (range), y | 64 (23-86) | 55 (20-76) | .18 |
| Disease | .52 | ||
| B-cell lymphoma (n = 40) | 12 (30) | 28 (70) | |
| B-cell acute lymphoblastic leukemia (n = 37) | 7 (19) | 30 (81) | |
| Multiple myeloma (n = 6) | 1 (17) | 5 (83) | |
| >3 prior lines of therapy | 7 (16) | 38 (84) | .07 |
| Baseline cytopenia | 14 (19) | 59 (81) | .01 |
| CAR construct | .008 | ||
| Axicabtagene ciloleucel (n = 30) | 5 (17) | 25 (83) | |
| Tisagenlecleucel (n = 10) | 7 (70) | 3 (30) | |
| 19-28z CAR T cells (n = 37) | 7 (19) | 30 (81) | |
| anti-BCMA CAR T cells (n = 6) | 1 (17) | 5 (83) | |
| Lymphodepleting chemotherapy | .32 | ||
| Fludarabine and cyclophosphamide (n = 51) | 12 (24) | 39 (76) | |
| High-dose cyclophosphamide* (n = 31) | 7 (23) | 24 (77) | |
| Bendamustine (n = 1) | 1 (100) | 0 (0) | |
| CRS grade† | .08 | ||
| 0 (n = 13) | 4 (31) | 9 (69) | |
| 1-2 (n = 51) | 15 (29) | 36 (71) | |
| 3-4 (n = 19) | 1 (5) | 18 (95) | |
| ICANS grade† | <.001 | ||
| 0 (n = 36) | 16 (44) | 20 (56) | |
| 1-2 (n = 17) | 3 (18) | 14 (82) | |
| 3-4 (n = 30) | 1 (3) | 29 (97) | |
| Grade ≥3 CRS/ICANS | 2 (6) | 31 (94) | .002 |
| Prior autologous or allogeneic stem cell transplantation | 4 (13) | 26 (87) | .11 |
| Peak CRP, median (range), mg/L | 9.6 (1.2-29.1), n = 15 | 13.7 (0.3-21 024), n = 57 | .03 |
| Peak ferritin, median (range), ng/mL | 312 (56-4923), n = 16 | 1 899 (22-546 080), n = 53 | .004 |
| . | Complete count recovery (n = 20) . | No complete count recovery (n = 63) . | P . |
|---|---|---|---|
| Age, median (range), y | 64 (23-86) | 55 (20-76) | .18 |
| Disease | .52 | ||
| B-cell lymphoma (n = 40) | 12 (30) | 28 (70) | |
| B-cell acute lymphoblastic leukemia (n = 37) | 7 (19) | 30 (81) | |
| Multiple myeloma (n = 6) | 1 (17) | 5 (83) | |
| >3 prior lines of therapy | 7 (16) | 38 (84) | .07 |
| Baseline cytopenia | 14 (19) | 59 (81) | .01 |
| CAR construct | .008 | ||
| Axicabtagene ciloleucel (n = 30) | 5 (17) | 25 (83) | |
| Tisagenlecleucel (n = 10) | 7 (70) | 3 (30) | |
| 19-28z CAR T cells (n = 37) | 7 (19) | 30 (81) | |
| anti-BCMA CAR T cells (n = 6) | 1 (17) | 5 (83) | |
| Lymphodepleting chemotherapy | .32 | ||
| Fludarabine and cyclophosphamide (n = 51) | 12 (24) | 39 (76) | |
| High-dose cyclophosphamide* (n = 31) | 7 (23) | 24 (77) | |
| Bendamustine (n = 1) | 1 (100) | 0 (0) | |
| CRS grade† | .08 | ||
| 0 (n = 13) | 4 (31) | 9 (69) | |
| 1-2 (n = 51) | 15 (29) | 36 (71) | |
| 3-4 (n = 19) | 1 (5) | 18 (95) | |
| ICANS grade† | <.001 | ||
| 0 (n = 36) | 16 (44) | 20 (56) | |
| 1-2 (n = 17) | 3 (18) | 14 (82) | |
| 3-4 (n = 30) | 1 (3) | 29 (97) | |
| Grade ≥3 CRS/ICANS | 2 (6) | 31 (94) | .002 |
| Prior autologous or allogeneic stem cell transplantation | 4 (13) | 26 (87) | .11 |
| Peak CRP, median (range), mg/L | 9.6 (1.2-29.1), n = 15 | 13.7 (0.3-21 024), n = 57 | .03 |
| Peak ferritin, median (range), ng/mL | 312 (56-4923), n = 16 | 1 899 (22-546 080), n = 53 | .004 |